News|Webcasts|April 22, 2025

Precision In, Precision Out: Elevated Kitting Strategies for Clinical Trials

Webinar Date/Time: Thursday, May 22, 2025 at 11:00 AM EST | 5:00 PM CEST

Industry experts from Precision for Medicine will share practical strategies for navigating the complexities of sample management in early-phase trials. Learn how to develop customized sample collection solutions that translate scientific requirements into clear, practical procedures for clinical sites, ensuring every sample is handled correctly and supporting robust biomarker strategies.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/precision-in

Event overview:
In this webinar, industry experts from Precision for Medicine will share practical strategies for designing, deploying, and managing clinical trial kits. The session covers the complete process — from early protocol review and detailed kit design to hands-on case studies — highlighting how overlooking basic elements (such as using appropriate collection devices, ensuring proper sample preservation, maintaining temperature-controlled transit and providing clear kit designs and instructions) can compromise high-value translational assays and delay critical data needed for dose escalation. Attendees will learn best practices to ensure that every sample is handled correctly from the first patient onward, with an emphasis on methods that address logistical challenges and support robust biomarker strategies in complex early-phase trials.


Key Learning Objectives

  • Understand the challenge of designing collection kits that are logical for the clinical sites’ needs and ensure that all samples are collected and handled correctly.
  • Understand the impact of improper sample preservation on assay integrity.
  • Learn about customized sample collection solutions based on clinical protocol requirements.
  • Hear about strategies for managing last-minute protocol changes with agile solutions.
  • Learn effective approaches for training and supporting clinical sites on kit usage.
  • Learn about integrating sample management within broader biomarker operational strategies.


Speakers:

Deb Phippard, PhDC
hief Scientific Officer
Precision for Medicine

Deb Phippard, PhD, is the chief scientific officer at Precision for Medicine. With over 25 years of experience in biotechnology and clinical translational research, she is a veteran in the pharma industry and an expert in biomarker-driven clinical trial design and execution. Phippard leads biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. She spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.

Christie Bongel, MS, CT(ASCP)
Site Director—Histology
Precision for Medicine

Christie Bongel, MS, CT(ASCP), is the site director at Precision for Medicine’s IHC Center of Excellence in North Carolina. With nearly two decades of experience in research and clinical medicine, she is an expert in cytology, laboratory medicine, and molecular diagnostics. Bongel excels in managing scientific operations and collaborating with clients. She leads a dedicated team focused on delivering life-changing outcomes for patients.


Register Free: https://www.appliedclinicaltrialsonline.com/act_w/precision-in

Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.